Moderna Financial Statements
NASDAQ: MRNAHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Moderna revenue and earnings
In fiscal 2025, Moderna generated $1.94 billion in revenue, down 39.9% from fiscal 2024, its first annual decline since 2024. Moderna reported a net loss of $2.82 billion, compared with a loss of $3.56 billion a year earlier. Gross margin was 55.3% (up from 54.8%) and operating margin -158.1%.
Diluted earnings per share came in at -$7.26. Over the last 5 fiscal years, MRNA's revenue has grown at a 19.3% compound annual rate.
Summary generated from market data by MetaCap's automated system. Methodology
Moderna income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.94B | 3.24B | 6.85B | 19.26B | 18.47B | 803.00M | 60.00M | 135.07M | 205.82M | 108.40M |
| Revenue growth (YoY) | -39.93% | -52.75% | -64.45% | +4.29% | +2200.25% | +1238.33% | -55.58% | -34.38% | +89.88% | — |
| Cost of Revenue | 868.00M | 1.46B | 4.69B | 5.42B | 2.62B | 8.00M | 0 | 0 | — | — |
| Gross Profit | 1.08B | 1.77B | 2.15B | 13.85B | 15.85B | 795.00M | 60.00M | 135.07M | — | — |
| Operating Expenses | 4.15B | 5.72B | 6.39B | 4.43B | 2.56B | 1.56B | 605.93M | 548.33M | 475.18M | 332.17M |
| Research & Development | 3.13B | 4.54B | 4.84B | 3.29B | 1.99B | 1.37B | 496.00M | 454.08M | 410.46M | 274.72M |
| Operating Income | -3.07B | -3.94B | -4.24B | 9.42B | 13.30B | -763.00M | -546.00M | -413.27M | -269.36M | -223.77M |
| Other Income (Expense) | -8.00M | -87.00M | -124.00M | -45.00M | -29.00M | -6.00M | -8.00M | 1.83M | -1.88M | -2.71M |
| Pretax Income | -2.77B | -3.61B | -3.94B | 9.57B | 13.29B | -744.00M | -515.00M | -384.41M | -256.00M | -215.17M |
| Income Tax | 54.00M | -46.00M | 772.00M | 1.21B | 1.08B | 3.00M | -1.00M | 326.00K | -80.00K | 1.04M |
| Net Income | -2.82B | -3.56B | -4.71B | 8.36B | 12.20B | -747.00M | -514.00M | -384.73M | -255.92M | -216.21M |
| Net Income growth (YoY) | — | — | -156.37% | -31.47% | — | — | — | — | — | — |
| EPS (Basic) | -7.26 | -9.28 | -12.33 | 21.26 | 30.31 | -1.96 | -1.55 | -4.95 | -4.18 | -3.79 |
| EPS (Diluted) | -7.26 | -9.28 | -12.33 | 20.12 | 28.29 | -1.96 | -1.55 | -4.95 | -4.18 | -3.79 |
| Shares Outstanding (Basic) | 389.00M | 384.00M | 382.00M | 394.00M | 403.00M | 381.00M | 331.00M | 81.11M | 64.50M | 60.75M |
| Shares Outstanding (Diluted) | 389.00M | 384.00M | 382.00M | 416.00M | 431.00M | 381.00M | 331.00M | 81.11M | 64.50M | 60.75M |
| EBITDA | -2.86B | -3.76B | -3.62B | 9.77B | 13.53B | -732.00M | -515.00M | -388.40M | -248.82M | -208.66M |
| Gross Margin | 55.35% | 54.76% | 31.47% | 71.88% | 85.83% | 99.00% | 100.00% | 100.00% | — | — |
| Operating Margin | -158.13% | -121.91% | -61.90% | 48.90% | 71.98% | -95.02% | -910.00% | -305.97% | -130.87% | -206.44% |
| Net Margin | -145.16% | -110.04% | -68.84% | 43.41% | 66.06% | -93.03% | -856.67% | -284.84% | -124.34% | -199.46% |
This table shows 10 annual periods of Moderna's income statement, from FY 2025 back to FY 2016, across 18 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow MRNA's reporting calendar. What is a income statement?